![]() |
Amgen Presents New XGEVA? (Denosumab) Breast Cancer Skeletal-Related Event Prevention
Amgen (Nasdaq: AMGN) announced results from new analyses comparing XGEVA? (denosumab), the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa® (zoledronic acid)...
More... |
| All times are GMT -7. The time now is 02:02 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021